|Dr. Mark A. Velleca||CEO, Pres & Director||878.21k||175.68k||1964|
|Ms. Jennifer K. Moses||Chief Financial Officer||441.6k||75.54k||1975|
|Dr. Rajesh K. Malik||Chief Medical Officer and Sr. VP of R&D||560.17k||136.78k||1959|
|Mr. Mark Avagliano||Chief Bus. Officer||559.74k||N/A||1976|
|Mr. Terry L. Murdock||Chief Operating Officer||N/A||N/A||1960|
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.